What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Polycomb Proteins: Epigenetic Regulators of Gene Silencing

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Polycomb Proteins

Polycomb proteins are a family of epigenetic regulators that maintain heritable gene repression across cell divisions. They were first identified in Drosophila melanogaster through genetic screens for mutations that caused homeotic transformations—body segments developing with the identity of other segments. The classic example is the Polycomb (Pc) mutation, which causes ectopic expression of homeotic (Hox) genes, leading to flies with extra sex combs on the second and third legs. This phenotype revealed that Polycomb proteins normally function to keep Hox genes silenced in cells where they should not be expressed.

The fundamental insight from these early studies was that Polycomb proteins do not establish initial patterns of gene expression; rather, they maintain the silenced state once it has been established by transient developmental signals. This maintenance function is the defining feature of Polycomb-mediated repression: it is mitotically heritable, meaning that once a gene is silenced by Polycomb in a progenitor cell, its daughter cells will also maintain that silenced state.

Historical Discovery

The Polycomb story began in the 1940s with Pamela Lewis's description of the Polycomb mutant in Drosophila. In the 1980s, cloning of the Polycomb gene revealed that it encoded a protein with a chromodomain, a motif later found to bind methylated histones. Subsequent genetic screens identified additional members of the Polycomb group (PcG) and the antagonistic trithorax group (TrxG), which maintain active gene expression. The mammalian homologs were identified in the 1990s, and biochemical purification revealed that Polycomb proteins assemble into two principal multiprotein complexes: Polycomb Repressive Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2).

Core Components of Polycomb Repressive Complexes

The two complexes are biochemically and functionally distinct. PRC2 is a methyltransferase that deposits trimethylation on lysine 27 of histone H3 (H3K27me3), a modification associated with facultative heterochromatin. PRC1 recognizes this mark and catalyzes monoubiquitination of histone H2A at lysine 119 (H2AK119ub1), which contributes to chromatin compaction and transcriptional repression. The interplay between these two complexes creates a self-reinforcing silencing loop that is remarkably stable yet reversible under the right developmental cues.

Polycomb Repressive Complex 1 (PRC1)

PRC1 is a multi-subunit complex with both enzymatic and structural functions. Its canonical form consists of four core subunits: a Ring finger protein (RING1A or RING1B), a Polycomb group RING finger protein (PCGF1–6), a Polyhomeotic homolog (PHC1–3), and a Chromobox protein (CBX2, CBX4, CBX6, CBX7, or CBX8). The RING1A/B subunits are the catalytic components responsible for ubiquitinating histone H2A.

Subunits and Variants

The subunit composition of PRC1 is not fixed. Six distinct PCGF paralogs define at least six different PRC1 variants, each with different accessory proteins and genomic targeting preferences. The canonical PRC1 complexes contain CBX proteins, which bind to H3K27me3 via their chromodomains, linking PRC1 recruitment to PRC2 activity. Non-canonical PRC1 complexes, in contrast, contain RYBP or YAF2 instead of CBX proteins and can be recruited to chromatin independently of H3K27me3, often through sequence-specific transcription factors.

The RING1B subunit (also called RNF2) is the primary E3 ligase in most PRC1 complexes. Its catalytic activity requires dimerization with a PCGF partner, which stabilizes the RING domain and positions the ubiquitin-conjugating enzyme (E2) for catalysis. The reaction transfers ubiquitin from the E2 enzyme UBE2D3 or UBE2E2 to lysine 119 of histone H2A. This monoubiquitination—the addition of a single ubiquitin moiety, not a polyubiquitin chain—is the hallmark enzymatic activity of PRC1.

H2A Ubiquitination

H2AK119ub1 is deposited on nucleosomes at Polycomb target genes and serves multiple functions. It directly compacts chromatin by altering nucleosome dynamics, and it recruits additional repressive factors. The deubiquitinase PR-DUB (containing BAP1 and ASXL1) removes this mark, creating a dynamic cycle of ubiquitination and deubiquitination that is important for proper Polycomb function. Complete loss of H2AK119ub1, as seen in RING1B knockout cells, results in derepression of Polycomb target genes, though the extent of derepression varies by cell type and gene.

The catalytic activity of PRC1 is regulated by allosteric mechanisms. The binding of H3K27me3 to CBX proteins enhances PRC1 activity, while phosphorylation of RING1B by cyclin-dependent kinases can inhibit it. Additionally, the ubiquitination of H2A is counteracted by the activity of deubiquitinases, ensuring that the mark is dynamically regulated rather than constitutively present.

Polycomb Repressive Complex 2 (PRC2)

PRC2 is a four-subunit methyltransferase complex that catalyzes the mono-, di-, and trimethylation of histone H3 at lysine 27. The core subunits are EZH1 or EZH2 (the catalytic subunits), EED, SUZ12, and RBBP4 or RBBP7. EZH2 is the predominant catalytic subunit in proliferating cells, while EZH1 is more abundant in differentiated tissues.

Core Subunits

EZH2 contains the SET domain responsible for methyltransferase activity. However, EZH2 alone is catalytically inactive; it requires assembly with EED and SUZ12 to form a functional enzyme. EED recognizes H3K27me3 through its WD40 domain, creating a positive feedback loop: PRC2 that has already deposited H3K27me3 can bind to this mark and become allosterically activated, leading to processive methylation and spreading of the mark along chromatin. SUZ12 provides structural stability and contains a zinc finger domain that contributes to nucleosome binding. RBBP4/7 bind to histone H4 and assist in nucleosome recognition.

The enzymatic mechanism involves the transfer of a methyl group from S-adenosylmethionine (SAM) to the ε-amino group of lysine 27. The reaction proceeds processively: PRC2 can catalyze mono-, di-, and trimethylation without dissociating from the nucleosome. The allosteric activation by EED binding to H3K27me3 is critical for efficient trimethylation; in the absence of this stimulation, PRC2 primarily produces H3K27me1 and H3K27me2.

H3K27 Methylation

H3K27me3 is the defining chromatin mark of Polycomb repression. It is enriched at the promoters and gene bodies of developmental transcription factor genes, particularly Hox clusters, and covers large genomic domains that can span tens to hundreds of kilobases. H3K27me2 is more broadly distributed across the genome and is thought to prevent spurious activation of lineage-inappropriate genes. H3K27me1 is enriched in gene bodies of actively transcribed genes and may play a role in transcriptional elongation.

The deposition of H3K27me3 by PRC2 is antagonized by the demethylases KDM6A (UTX) and KDM6B (JMJD3), which remove methyl groups from H3K27. This antagonism is critical for developmental transitions, where Polycomb silencing must be reversed to allow gene activation. Additionally, the H3K27 methyl mark can be phosphorylated at serine 28 (H3K27me3S28ph) by kinases such as MSK1/2, which disrupts the binding of CBX proteins to H3K27me3 and promotes transcriptional activation.

Mechanism of Polycomb-Mediated Gene Silencing

Polycomb-mediated silencing is a multi-step process that involves recruitment to target genes, deposition of histone modifications, chromatin compaction, and maintenance of the repressed state through cell division.

Recruitment to Target Genes

Polycomb complexes are recruited to thousands of genomic loci, but the mechanisms of recruitment are diverse and context-dependent. In Drosophila, Polycomb Response Elements (PREs) are DNA sequences that recruit PcG proteins. These elements contain binding sites for sequence-specific transcription factors such as Pleiohomeotic (Pho), GAGA factor (GAF), and Zeste. In mammals, the situation is more complex; no single canonical PRE has been identified, and recruitment appears to involve multiple redundant mechanisms.

Three major recruitment pathways have been described in mammals:

Sequence-specific transcription factors: Proteins such as YY1 (the mammalian homolog of Pho), SNAIL, and REST can recruit PRC2 to specific loci. For example, REST recruits PRC2 to neuronal genes in non-neuronal cells, maintaining them in a silenced state.

CpG islands: PRC2 has an intrinsic affinity for CpG-rich DNA sequences, particularly those that are unmethylated. The SUZ12 subunit and the EZH2 N-terminal region contribute to this DNA binding. This mechanism explains why Polycomb targets are enriched at CpG islands in mammalian genomes.

Long non-coding RNAs: Several lncRNAs, including XIST (in X-chromosome inactivation), KCNQ1OT1, and HOTAIR, can recruit PRC2 to specific genomic regions. The RNA binds to PRC2 subunits, particularly EZH2 and SUZ12, and guides the complex to target loci. However, the specificity and physiological relevance of RNA-mediated recruitment remain areas of active investigation.

Once recruited, PRC2 deposits H3K27me3, which is then recognized by CBX proteins in canonical PRC1 complexes. This sequential recruitment model—PRC2 first, then PRC1—is supported by biochemical and genetic evidence. However, non-canonical PRC1 complexes containing RYBP can be recruited independently of H3K27me3, and in some contexts, PRC1 recruitment precedes PRC2. The temporal order of recruitment is therefore context-dependent.

Chromatin Compaction and Maintenance

The deposition of H3K27me3 and H2AK119ub1 leads to chromatin compaction through several mechanisms. H2AK119ub1 directly compacts nucleosomal arrays in vitro, and the PHC subunits of PRC1 can oligomerize to bring distant nucleosomes together, forming higher-order chromatin structures. This compaction is visible by microscopy as Polycomb bodies—discrete nuclear foci where Polycomb target genes are clustered.

The maintenance of Polycomb silencing through DNA replication is an active area of research. During S phase, histone modifications are diluted as new, unmodified histones are deposited. The propagation of H3K27me3 is thought to occur through the EED-mediated positive feedback loop: PRC2 bound to parental H3K27me3 nucleosomes is allosterically activated and methylates adjacent new histones. Similarly, H2AK119ub1 on parental nucleosomes may recruit PRC1 to modify new nucleosomes. This self-propagating mechanism ensures that the silenced state is faithfully inherited by daughter cells.

The maintenance of silencing also requires the exclusion of transcriptional activators and RNA Polymerase II. Polycomb-repressed genes are characterized by the absence of H3K4me3 (a mark of active promoters) and the presence of stalled or absent RNA Polymerase II. The chromatin compaction mediated by Polycomb complexes physically impedes the binding of transcription factors and the transcriptional machinery, reinforcing the silenced state.

Polycomb Proteins in Development and Cell Identity

Polycomb proteins are essential for embryonic development and the maintenance of cell identity. Their ability to maintain gene repression across cell divisions makes them critical for ensuring that cells retain their differentiated state and do not inappropriately express genes from other lineages.

Role in Embryonic Development

During embryogenesis, Polycomb proteins establish and maintain the correct expression patterns of Hox genes, which specify the anterior-posterior body axis. In mice, knockout of PRC2 components such as EED or EZH2 results in embryonic lethality around the time of gastrulation, with severe defects in axis formation and somitogenesis. Similarly, knockout of RING1B, the catalytic subunit of PRC1, causes embryonic lethality at gastrulation.

The role of Polycomb in Hox gene regulation is particularly well characterized. Hox genes are arranged in clusters, and their expression domains along the anterior-posterior axis are established by graded morphogen signals during early development. Polycomb proteins then maintain these expression boundaries by silencing Hox genes outside their appropriate domains. In Polycomb mutants, Hox genes are ectopically expressed, leading to homeotic transformations—segments developing with the identity of other segments.

Polycomb proteins also regulate the timing of developmental gene activation. In embryonic stem cells, developmental regulator genes are marked by H3K27me3 but are not fully silenced; they exist in a "poised" state characterized by the presence of both H3K27me3 and H3K4me3 (a bivalent domain). This bivalent state keeps genes repressed but poised for rapid activation upon differentiation signals. As cells differentiate, bivalent domains resolve: genes that should remain silent lose H3K4me3 and retain H3K27me3, while genes that should be activated lose H3K27me3 and retain H3K4me3.

Stem Cell Pluripotency

In embryonic stem cells (ESCs), Polycomb proteins maintain pluripotency by silencing lineage-specific genes. The core pluripotency transcription factors OCT4, SOX2, and NANOG occupy the promoters of many Polycomb target genes, and their binding is required for the establishment of bivalent domains. This creates a regulatory network in which pluripotency factors recruit Polycomb to silence differentiation genes, while Polycomb in turn maintains the expression of pluripotency genes by silencing their repressors.

The balance between Polycomb-mediated silencing and transcriptional activation is critical for differentiation. When ESCs are induced to differentiate, Polycomb target genes that are required for the new cell fate are rapidly activated, while those that should remain silent are maintained in a repressed state. This dynamic regulation requires the coordinated action of Polycomb complexes, histone demethylases, and chromatin remodelers.

In somatic cells, Polycomb proteins maintain cell identity by silencing genes from other lineages. For example, in fibroblasts, neuronal genes are maintained in a Polycomb-repressed state; upon expression of neuronal transcription factors, these genes can be activated, but only if Polycomb silencing is first reversed. This explains why cellular reprogramming to pluripotency requires the downregulation of Polycomb activity and the resetting of epigenetic marks.

Polycomb Proteins in Human Disease

Given their central role in gene regulation and development, it is not surprising that Polycomb dysregulation is associated with a wide range of human diseases, particularly cancer.

Cancer and PRC2 Mutations

Polycomb proteins can act as both oncogenes and tumor suppressors, depending on the context. Overexpression of EZH2 is observed in many cancers, including prostate, breast, bladder, and lymphoma. In these contexts, EZH2 promotes cell proliferation and survival by silencing tumor suppressor genes. The oncogenic activity of EZH2 is often enhanced by activating mutations, particularly in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, where mutations at tyrosine 641 (Y641) and alanine 677 (A677) in the SET domain alter substrate specificity and increase H3K27me3 levels.

Paradoxically, loss-of-function mutations in PRC2 components are also found in cancer. Inactivating mutations in EZH2, SUZ12, and EED are common in malignant peripheral nerve sheath tumors (MPNST) and some leukemias. In these contexts, loss of PRC2 function leads to genome-wide loss of H3K27me3 and activation of oncogenic pathways. This dual role of PRC2 as both oncogene and tumor suppressor reflects the context-dependent functions of Polycomb in different cell types and cancer types.

The therapeutic targeting of PRC2 is an active area of drug development. Several small-molecule inhibitors of EZH2, such as tazemetostat, have been developed and approved for the treatment of epithelioid sarcoma and follicular lymphoma. These inhibitors compete with SAM for binding to the EZH2 active site and selectively inhibit H3K27 methylation. Clinical trials have shown promising responses in patients with EZH2-mutant lymphomas, though resistance mechanisms involving secondary mutations in EZH2 or upregulation of EZH1 are emerging.

Developmental Syndromes

Germline mutations in Polycomb genes cause several developmental disorders. Weaver syndrome is caused by mutations in EZH2 and is characterized by overgrowth, intellectual disability, and distinctive facial features. The mutations are typically loss-of-function, suggesting that reduced PRC2 activity during development leads to the observed phenotypes. Similarly, mutations in EED and SUZ12 cause Cohen-Gibson syndrome and Imagawa-Matsumoto syndrome, respectively, both of which share features with Weaver syndrome.

Mutations in PRC1 components are also associated with developmental disorders. Mutations in RING1B cause a neurodevelopmental disorder characterized by intellectual disability and speech delay. Mutations in the CBX family members have been linked to various neurodevelopmental phenotypes, though the genotype-phenotype correlations are less well established.

Beyond cancer and developmental syndromes, Polycomb dysregulation has been implicated in other diseases. Altered Polycomb activity is observed in neurodegenerative disorders, where loss of Polycomb-mediated silencing may contribute to aberrant gene expression in neurons. Polycomb proteins also play roles in inflammation and immune responses, and their dysregulation has been linked to autoimmune diseases.

Methods to Study Polycomb Proteins

Investigating Polycomb function requires a combination of biochemical, genomic, and genetic approaches. The following techniques are commonly used in the field.

Chromatin Immunoprecipitation

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) is the gold standard for mapping Polycomb protein binding and histone modifications genome-wide. The protocol involves crosslinking proteins to DNA with formaldehyde, shearing chromatin by sonication to fragments of 200–600 base pairs, and immunoprecipitating the protein of interest with a specific antibody. After reversing the crosslinks and purifying the DNA, the enriched fragments are sequenced and mapped to the genome.

For histone modifications such as H3K27me3, the ChIP protocol is straightforward: cells are crosslinked, chromatin is sheared, and the modification is immunoprecipitated with a validated antibody. For Polycomb proteins themselves, the protocol is more challenging because the proteins are large and may not be efficiently crosslinked to DNA. In such cases, native ChIP (without crosslinking) or ChIP using crosslinkers with longer spacer arms may be required.

A typical ChIP-seq experiment requires 1–10 million cells per immunoprecipitation. The quality of the antibody is critical; antibodies that recognize H3K27me3 must distinguish it from H3K27me1 and H3K27me2, which requires rigorous validation by peptide arrays or dot blots. The sequencing depth for histone modification ChIP-seq is typically 20–40 million reads, while for transcription factors, 10–20 million reads may suffice.

Knockout and Knockdown Approaches

Genetic perturbation is essential for determining the function of Polycomb proteins. The most definitive approach is the generation of knockout cell lines or organisms. In mice, conditional knockout alleles allow tissue-specific deletion of Polycomb genes using Cre-loxP recombination. For example, Ezh2 floxed mice can be crossed with tissue-specific Cre drivers to delete EZH2 in specific cell types.

In cultured cells, CRISPR-Cas9-mediated gene editing is the method of choice for generating knockout lines. The guide RNA is designed to target the catalytic domain of the Polycomb gene, and successful knockout is confirmed by western blot and functional assays. For example, RING1B knockout in mouse ESCs results in loss of H2AK119ub1 and derepression of Polycomb target genes, which can be quantified by RNA-seq.

Knockdown approaches using short hairpin RNA (shRNA) or small interfering RNA (siRNA) are useful for acute depletion, particularly when complete knockout is lethal. However, knockdown is typically incomplete, and residual protein may be sufficient to maintain some Polycomb function. The choice between knockout and knockdown depends on the experimental question: knockout is preferred for definitive loss-of-function studies, while knockdown is useful for studying acute effects and for genes essential for cell survival.

Additional methods include:

RNA-seq: Quantifies transcript levels to assess the effects of Polycomb perturbation on gene expression. Differential expression analysis identifies genes that are derepressed upon loss of Polycomb function.
CUT&RUN: An alternative to ChIP that uses a protein A-MNase fusion to cleave chromatin at antibody-bound sites. It requires fewer cells than ChIP and has lower background.
Hi-C: Maps chromatin interactions genome-wide and can reveal the effects of Polycomb on chromatin architecture, particularly the formation of Polycomb-associated domains.
Mass spectrometry: Identifies Polycomb-interacting proteins and post-translational modifications on Polycomb subunits.

Common Pitfalls and Misconceptions

Several misconceptions about Polycomb proteins are common among students and even researchers. Understanding these pitfalls is essential for interpreting experimental data and designing rigorous studies.

Polycomb and DNA Methylation

A frequent misconception is that Polycomb silencing is equivalent to DNA methylation. These are distinct mechanisms of epigenetic repression. DNA methylation occurs at cytosine residues in CpG dinucleotides and is mediated by DNA methyltransferases (DNMTs). Polycomb silencing is mediated by histone modifications and does not involve direct DNA methylation. In fact, Polycomb target genes are typically enriched at CpG islands that are unmethylated, and the presence of DNA methylation at CpG islands is generally incompatible with Polycomb binding.

The relationship between Polycomb and DNA methylation is complex. In cancer, Polycomb target genes can become aberrantly DNA-methylated, leading to stable silencing that is resistant to reactivation. This "epigenetic switching" from Polycomb-mediated repression to DNA methylation-mediated repression is thought to contribute to tumor suppressor gene silencing in cancer. However, in normal cells, Polycomb and DNA methylation are largely mutually exclusive.

Dynamic vs. Static Silencing

Another misconception is that Polycomb silencing is a static, irreversible state. In reality, Polycomb repression is highly dynamic. Histone modifications are continuously deposited and removed, and Polycomb complexes are in constant flux on chromatin. The H3K27me3 mark has a half-life of several hours to days, depending on the cell type and genomic location, and the H2AK119ub1 mark is turned over even more rapidly.

The dynamic nature of Polycomb silencing is essential for development. When a cell receives a differentiation signal, Polycomb target genes must be rapidly activated. This requires the removal of H3K27me3 by demethylases, the eviction of Polycomb complexes, and the deposition of active histone marks. The reversibility of Polycomb silencing is also exploited in cellular reprogramming, where the resetting of Polycomb marks is required for the establishment of pluripotency.

The Simplicity of Recruitment

A third misconception is that Polycomb recruitment is a simple, linear process. In reality, recruitment is highly context-dependent and involves multiple redundant mechanisms. The classic model of PRC2 recruiting PRC1 through H3K27me3 recognition is an oversimplification. Non-canonical PRC1 complexes can be recruited independently of PRC2, and in some contexts, PRC1 recruitment precedes and is required for PRC2 recruitment.

The diversity of PRC1 complexes adds another layer of complexity. With six PCGF paralogs, multiple CBX proteins, and various accessory subunits, the number of possible PRC1 complexes is large. Each variant may have different targeting rules, different enzymatic activities, and different functions. Studying Polycomb function therefore requires careful consideration of which complex is being studied and in which cellular context.

Additional Pitfalls

Antibody specificity: Many commercial antibodies against Polycomb proteins and histone modifications are not specific. Validation by peptide competition or knockout controls is essential.
Cell line artifacts: Polycomb protein levels and genomic targeting vary between cell lines and culture conditions. Results obtained in one cell line may not generalize to others.
Overexpression artifacts: Overexpression of Polycomb proteins can lead to non-physiological targeting and activity. Studies should use endogenous expression levels whenever possible.
Bivalent domains misinterpretation: The presence of both H3K27me3 and H3K4me3 at a locus does not necessarily mean the gene is "poised" for activation. Bivalent domains may also represent a state of transcriptional noise or incomplete silencing.

Summary and Key Takeaways

Polycomb proteins are fundamental regulators of gene expression that maintain heritable silencing of developmental genes. They function through two principal complexes—PRC1 and PRC2—that deposit histone modifications and compact chromatin. The interplay between these complexes creates a self-reinforcing silencing system that is essential for development, cell identity, and disease prevention.

Frequently Asked Questions

What are polycomb proteins?

Polycomb proteins are epigenetic regulators that maintain gene silencing. They were first discovered in fruit flies as regulators of Hox genes and are conserved from flies to humans. They function as multiprotein complexes—PRC1 and PRC2—that modify histones and compact chromatin to keep genes in a repressed state.

How do polycomb proteins silence genes?

Polycomb proteins silence genes through a multi-step process. PRC2 deposits H3K27me3 on nucleosomes, which is recognized by PRC1. PRC1 then ubiquitinates H2A at lysine 119, leading to chromatin compaction and transcriptional repression. The marks are maintained through cell division, ensuring that silencing is inherited by daughter cells.

What is the difference between PRC1 and PRC2?

PRC1 and PRC2 are distinct complexes with different compositions and enzymatic activities. PRC2 contains EZH1/2, EED, SUZ12, and RBBP4/7 and catalyzes H3K27 methylation. PRC1 contains RING1A/B, PCGF, PHC, and CBX or RYBP and catalyzes H2AK119 ubiquitination. PRC2 acts first to establish the H3K27me3 mark, which is then recognized by PRC1.

Are polycomb proteins only involved in gene silencing?

While Polycomb proteins are best known for gene silencing, they have additional functions. They regulate chromatin architecture, DNA replication timing, and DNA damage repair. Some Polycomb components can also activate gene expression in specific contexts, and non-canonical PRC1 complexes have functions beyond repression.

How are polycomb proteins studied?

Polycomb proteins are studied using a combination of approaches. ChIP-seq maps their genomic localization and histone modifications. RNA-seq measures the effects of Polycomb perturbation on gene expression. Genetic approaches, including knockout and knockdown, determine their functional requirements. Biochemical approaches identify interacting proteins and enzymatic activities.

What diseases are associated with polycomb protein dysfunction?

Polycomb dysregulation is associated with many cancers, including lymphoma, prostate cancer, and breast cancer. EZH2 is overexpressed or mutated in several cancer types, and PRC2 inhibitors are used clinically. Germline mutations in Polycomb genes cause developmental disorders such as Weaver syndrome. Polycomb dysfunction is also implicated in neurological and inflammatory diseases.

Key Takeaways

Polycomb proteins are evolutionarily conserved epigenetic regulators that maintain gene silencing through histone modification and chromatin compaction.
PRC2 deposits H3K27me3, and PRC1 catalyzes H2AK119ub1; these marks work together to establish and maintain repression.
Polycomb silencing is mitotically heritable, dynamic, and reversible, allowing for developmental plasticity.
Polycomb proteins are essential for Hox gene regulation, embryonic development, and stem cell pluripotency.
Dysregulation of Polycomb proteins contributes to cancer and developmental disorders, making them important therapeutic targets.
Polycomb recruitment is complex and context-dependent, involving transcription factors, CpG islands, and long non-coding RNAs.
Studying Polycomb function requires rigorous experimental approaches, including ChIP-seq, genetic perturbation, and careful antibody validation.